Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor

Oncogene volume 25, pages 260–270 (2006)Cite this article

Abstract

The oncoprotein SET participates in a diversity of cellular functions including cell proliferation. Its role on cell cycle progression is likely mediated by inhibiting cyclin B-cdk1 and the protein phosphatase 2A (PP2A). On identifying new SET cellular partners, we found that SET interacts in vitro and in vivo with the heterogeneous nuclear ribonucleoprotein A2 (hnRNPA2); a protein involved in various aspects of mRNA biogenesis. The SET-binding region of hnRNPA2 is the RNP1 sequence that belongs to the RNA-binding domain (RBD) of this protein. We also found that hnRNPA2 has much higher affinity for single-standed DNA than for SET. On analysing the effect of hnRNPA2 on PP2A inhibition by SET, we observed that hnRNPA2 cooperates with SET on PP2A inhibition. This is because we found that hnRNPA2 is also a PP2A inhibitor. HnRNPA2 interacts with PP2A by the RNP1 sequence; however, to inhibit PP2A activity, the complete RBD is needed. We also observed that overexpression of hnRNPA2 inhibits PP2A activity and stimulates cell proliferation. Interestingly, the overexpression of the complete RBD is sufficient to stimulate proliferation. As hnRNPA2 is overexpressed in a variety of human tumors, our results suggest that hnRNPA2 might participate in oncogenesis by stimulating cell proliferation.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Adler HT, Nallaseth FS, Walter G, Tkachuk DC . (1997). J Biol Chem 272: 28407–28414.

  • Ainger K, Avossa D, Diana AS, Barry C, Barbarese E, Carson JH . (1997). J Cell Biol 138: 1077–1087.

  • Beresford PJ, Zhang D, Oh DY, Fan Z, Greer EL, Russo ML et al. (2001). J Biol Chem 276: 43285–43293.

  • Bosser R, Faura M, Serratosa J, Renau-Piqueras J, Pruschy M, Bachs O . (1995). Mol Cell Biol 15: 661–670.

  • Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N et al. (2003). J Biol Chem 278: 1158–1164.

  • Chen W, Possemato R, Campbell KT, Plattner CA, Pallas DC, Hahn WC . (2004). Cancer Cell 5: 127–136.

  • Chou DM, Petersen P, Walter JC, Walter G . (2002). J Biol Chem 277: 40520–40527.

  • Clarke PR, Hoffmann I, Draetta G, Karsenti E . (1993). Mol Biol Cell 4: 397–411.

  • Dreyfuss G, Kim VN, Kataoka N . (2002). Nat Rev Mol Cell Biol 3: 195–205.

  • Elder RT, Yu M, Chen M, Zhu X, Yanagida M, Zhao Y . (2001). Virology 287: 359–370.

  • Estanyol JM, Jaumot M, Casanovas O, Rodriguez-Vilarrupla A, Agell N, Bachs O . (1999). J Biol Chem 274: 33161–33165.

  • Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J . (2003a). Cell 112: 659–672.

  • Fan Z, Beresford PJ, Zhang D, Lieberman J . (2002). Mol Cell Biol 22: 2810–2820.

  • Fan Z, Beresford PJ, Zhang D, Xu Z, Novina CD, Yoshida A et al. (2003b). Nat Immunol 4: 145–153.

  • Fielding P, Turnbull L, Prime W, Walshaw M, Field JK . (1999). Clin Cancer Res 5: 4048–4052.

  • Ford LP, Wright WE, Shay JW . (2002). Oncogene 21: 580–583.

  • Janssens V, Goris J . (2001). Biochem J 353: 417–439.

  • Kellogg DR, Kikuchi A, Fujii-Nakata T, Turck CW, Murray AW . (1995). J Cell Biol 130: 661–673.

  • Kinoshita N, Yamano H, Niwa H, Yoshida T, Yanagida M . (1993). Genes Dev 7: 1059–1071.

  • Krecic AM, Swanson MS . (1999). Curr Opin Cell Biol 11: 363–371.

  • Kutney SN, Hong R, Macfarlan T, Chakravarti D . (2004). J Biol Chem 279: 30850–30855.

  • Kwon S, Barbarese E, Carson JH . (1999). J Cell Biol 147: 247–256.

  • Li M, Makkinje A, Damuni Z . (1996a). Biochemistry 35: 6998–7002.

  • Li M, Makkinje A, Damuni Z . (1996b). J Biol Chem 271: 11059–11062.

  • Lieberman J, Fan Z . (2003). Curr Opin Immunol 15: 553–559.

  • Matsumoto K, Nagata K, Ui M, Hanaoka F . (1993). J Biol Chem 268: 10582–10587.

  • Millward TA, Zolnierowicz S, Hemmings BA . (1999). Trends Biochem Sci 24: 186–191.

  • Moran-Jones K, Wayman L, Kennedy DD, Reddel RR, Sara S, Snee MJ et al. (2005). Nucleic Acids Res 33: 486–496.

  • Mulshine JL, De Luca LM, Dedrick RL, Tockman MS, Webster R, Placke ME . (2000). Cancer 89: 2465–2467.

  • Okuwaki M, Nagata K . (1998). J Biol Chem 273: 34511–34518.

  • Pandey AV, Mellon SH, Miller WL . (2003). J Biol Chem 278: 2837–2844.

  • Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, Toutant J et al. (2003). Cancer Res 63: 7679–7688.

  • Qu D, Li Q, Lim HY, Cheung NS, Li R, Wang JH et al. (2002). J Biol Chem 277: 7324–7332.

  • Sanchez-Piris M, Posas F, Alemany V, Winge I, Hidalgo E, Bachs O et al. (2002). J Biol Chem 277: 17722–17727.

  • Schonthal A, Feramisco JR . (1993). Oncogene 8: 433–441.

  • Schonthal AH . (2001). Cancer Lett 170: 1–13.

  • Seo SB, McNamara P, Heo S, Turner A, Lane WS, Chakravarti D . (2001). Cell 104: 119–130.

  • Shikama N, Chan HM, Krstic-Demonacos M, Smith L, Lee CW, Cairns W et al. (2000). Mol Cell Biol 20: 8933–8943.

  • Tockman MS, Mulshine JL, Piantadosi S, Erozan YS, Gupta PK, Ruckdeschel JC et al. (1997). Clin Cancer Res 3: 2237–2246.

  • Van Hoof C, Goris J . (2004). Cancer Cell 5: 105–106.

  • von Lindern M, van Baal S, Wiegant J, Raap A, Hagemeijer A, Grosveld G . (1992). Mol Cell Biol 12: 3346–3355.

  • Yan Y, Mumby MC . (1999). J Biol Chem 274: 31917–31924.

  • Yan-Sanders Y, Hammons GJ, Lyn-Cook BD . (2002). Cancer Lett 183: 215–220.

  • Zhou J, Allred DC, Avis I, Martinez A, Vos MD, Smith L et al. (2001). Breast Cancer Res Treat 66: 217–224.

Download references

Acknowledgements

This work was supported by Grants SAF 2002-00452, SAF 2003-08339 and GEN 2003-2043-C08-01 from the Ministerio de Educación y Ciencia, Spain. Financial support was also obtained from the Red temática del Cáncer, Instituto Carlos III, No. C03/10. Proteomic analysis was performed at the Proteomic Unit of the ‘Serveis cientifico-tècnics’ from the University of Barcelona.

Author information

Authors and Affiliations

  1. Department of Cell Biology and Pathology, Faculty of Medicine, University of Barcelona, Barcelona, Spain

    J Vera, M Jaumot, J M Estanyol, S Brun, N Agell & O Bachs

Authors
  1. J Vera
    View author publications

    Search author on:PubMed Google Scholar

  2. M Jaumot
    View author publications

    Search author on:PubMed Google Scholar

  3. J M Estanyol
    View author publications

    Search author on:PubMed Google Scholar

  4. S Brun
    View author publications

    Search author on:PubMed Google Scholar

  5. N Agell
    View author publications

    Search author on:PubMed Google Scholar

  6. O Bachs
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to O Bachs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vera, J., Jaumot, M., Estanyol, J. et al. Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. Oncogene 25, 260–270 (2006). https://doi.org/10.1038/sj.onc.1209050

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.onc.1209050

Keywords

This article is cited by

Search

Advanced search

Quick links